Traffic at the intersection of neurotrophic factor signaling and neurodegeneration

Trends in Neurosciences

Volumn 26, Issue 2, 2003, Pages 73-80

  Salehi, Ahmad ^a   Delcroix, Jean Dominique ^a   Mobley, William C ^a  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; CYCLIN DEPENDENT KINASE 5; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR RECEPTOR; NEUROTROPHIC FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PRESENILIN 1; PRESENILIN 2; PROTEASOME; PROTEIN P25; PROTEIN P75; TAU PROTEIN; UBIQUITIN;

ALZHEIMER DISEASE; CLINICAL FEATURE; DEGENERATIVE DISEASE; DOWN REGULATION; DOWN SYNDROME; GENE EXPRESSION; GENE MUTATION; LEWY BODY; NERVE DEGENERATION; NEUROFIBRILLARY TANGLE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; REVIEW;

ALZHEIMER DISEASE; ANIMALS; DOWN SYNDROME; HUMANS; MICE; NERVE GROWTH FACTORS; NEURODEGENERATIVE DISEASES; NEUROFIBRILLARY TANGLES; NEURONS; SENILE PLAQUES; SIGNAL TRANSDUCTION; TAU PROTEINS; TAUOPATHIES;

EID: 0037303935     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(02)00038-3     Document Type: Article

References (92)

1. Koppel, R. (2002) Alzheimer's disease: the cost to U.S. businesses in 2002. Alzheimer's Disease and Related Disorders Association (http://www.alz.org/Media/newsreleases/current/062702cost.html).
2. Wong P.C., et al. Genetically engineered mouse models of neurodegenerative diseases. Nat. Neurosci. 5:2002;633-639.
3. Appel S.H. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann. Neurol. 10:1981;499-505.
4. Sofroniew M.V., et al. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 24:2001;1217-1281.
5. Goedert M., et al. Nerve growth factor mRNA in peripheral and central rat tissues and in the human central nervous system: lesion effects in the rat brain and levels in Alzheimer's disease. Brain Res. 387:1986;85-92.
6. Phillips H.S., et al. BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer's disease. Neuron. 7:1991;695-702.
7. Jette N., et al. NGF mRNA is not decreased in frontal cortex from Alzheimer's disease patients. Mol. Brain Res. 25:1994;242-250.
8. Scott S.A., et al. Nerve growth factor in Alzheimer's disease: increased levels throughout the brain coupled with declines in nucleus basalis. J. Neurosci. 15:1995;6213-6221.
9. Wisniewski K.E., et al. Alzheimer's disease in Down's syndrome: clinicopathologic studies. Neurology. 35:1985;957-961.
10. Mann D.M., et al. Pathological evidence for neurotransmitter deficits in Down's syndrome of middle age. J. Ment. Defic. Res. 29:1985;125-135.
11. Reeves R.H., et al. A mouse model for Down syndrome exhibits learning and behaviour deficits. Nat. Genet. 11:1995;177-184.
12. Holtzman D.M., et al. Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc. Natl. Acad. Sci. U. S. A. 93:1996;13333-13338.
13. Cooper J.D., et al. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. Proc. Natl. Acad. Sci. U. S. A. 98:2001;10439-10444.
14. Granholm A.C., et al. Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Down's syndrome. Exp. Neurol. 161:2000;647-663.
15. Chen K.S., et al. Disruption of a single allele of the nerve growth factor gene results in atrophy of basal forebrain cholinergic neurons and memory deficits. J. Neurosci. 17:1997;7288-7296.
16. Fagan A.M., et al. A role for TrkA during maturation of striatal and basal forebrain cholinergic neurons in vivo. J. Neurosci. 17:1997;7644-7654.
17. Li Y., et al. Regulation of TrkA and ChAT expression in developing rat basal forebrain: evidence that both exogenous and endogenous NGF regulate differentiation of cholinergic neurons. J. Neurosci. 15:1995;2888-2905.
18. Capsoni S., et al. Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 97:2000;6826-6831.
19. Kasa P., et al. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 52:1997;511-535.
20. Siegel G.J., Chauhan N.B. Neurotrophic factors in Alzheimer's and Parkinson's disease brain. Brain Res. Rev. 33:2000;199-227.
21. Salehi A., et al. Co-localization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience. 75:1996;373-387.
22. Salehi A., et al. P75 neurotrophin receptor in the nucleus basalis of Meynert in relation to age, sex, and Alzheimer's disease. Exp. Neurol. 161:2000;245-258.
23. Mufson E.J., et al. Decreased trkA gene expression within basal forebrain neurons in Alzheimer's disease. NeuroReport. 8:1996;25-29.
24. Mufson E.J., et al. Loss of basal forebrain P75(NTR) immunoreactivity in subjects with mild cognitive impairment and Alzheimer's disease. J. Comp. Neurol. 443:2002;136-153.
25. Chu Y., et al. Down-regulation of trkA mRNA within nucleus basalis neurons in individuals with mild cognitive impairment and Alzheimer's disease. J. Comp. Neurol. 437:2001;296-307.
26. Mufson E.J., et al. Nerve growth factor in Alzheimer's disease: defective retrograde transport to nucleus basalis. NeuroReport. 6:1995;1063-1066.
27. Cavicchioli L., et al. NGF amplifies expression of NGF receptor messenger RNA in forebrain cholinergic neurons of rats. Eur. J. Neurosci. 1:1989;258-262.
28. Holtzman D.M., et al. p140trk mRNA marks NGF-responsive forebrain neurons: evidence that trk gene expression is induced by NGF. Neuron. 9:1992;465-478.
29. Tanzi R.E., Bertram L. New frontiers in Alzheimer's disease genetics. Neuron. 32:2001;181-184.
30. Terry R.D. Neuropathological changes in Alzheimer disease. Prog. Brain Res. 1994;383-390.
31. Otten U., et al. Cytokines and neurotrophins interact in normal and diseased states. Ann. New York Acad. Sci. 917:2000;322-330.
32. Mrak R.E., Griffin W.S. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol. Aging. 22:2001;903-908.
33. Cataldo A.M., et al. Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res. 640:1994;68-80.
34. Emmerling M.R., et al. The role of complement in Alzheimer's disease pathology. Biochim. Biophys. Acta. 1502:2000;158-171.
35. Su J.H., et al. Localization of heparan sulfate glycosaminoglycan and proteoglycan core protein in aged brain and Alzheimer's disease. Neuroscience. 51:1992;801-813.
36. Peress N.S., Perillo E. Differential expression of TGF-β 1, 2 and 3 isotypes in Alzheimer's disease: a comparative immunohistochemical study with cerebral infarction, aged human and mouse control brains. J. Neuropathol. Exp. Neurol. 54:1995;802-811.
37. Takami K., et al. Fibroblast growth factor receptor-1 expression in the cortex and hippocampus in Alzheimer's disease. Brain Res. 802:1998;89-97.
38. Yang A.J., et al. Loss of endosomal/lysosomal membrane impermeability is an early event in amyloid Aβ1-42 pathogenesis. J. Neurosci. Res. 52:1998;691-698.
39. Arriagada P.V., et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 42:1992;631-639.
40. Lee V.M., et al. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:2001;1121-1159.
41. Alonso A.C., et al. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 2:1996;783-787.
42. Buée L., et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Rev. 33:2000;95-130.
43. Mandelkow E.M., Mandelkow E. Tau in Alzheimer's disease. Trends Cell Biol. 8:1998;425-427.
44. Alonso A.D., et al. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. U. S. A. 94:1997;298-303.
45. Alonso A.D., et al. Interaction of tau isoforms with Alzheimer's disease abnormally hyperphosphorylated tau and in vitro phosphorylation into the disease-like protein. J. Biol. Chem. 276:2001;37967-37973.
46. Terry R.D., Wisniewski H.M. Gaitz C.M. Aging and the Brain. 1972;89-116 Plenum.
47. Flaherty D.B., et al. Phosphorylation of human tau protein by microtubule-associated kinases: GSK3beta and cdk5 are key participants. J. Neurosci. Res. 62:2000;463-472.
48. Yamaguchi H., et al. Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol. (Berl.). 92:1996;232-241.
49. Grimes C.A., Jope R.S. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65:2001;391-426.
50. Pei J.J., et al. Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J. Neuropathol. Exp. Neurol. 56:1997;70-78.
51. Lovestone S., et al. Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr. Biol. 4:1994;1077-1086.
52. Lucas J.J., et al. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 20:2001;27-39.
53. Crowder R.J., Freeman R.S. Glycogen synthase kinase-3 beta activity is critical for neuronal death caused by inhibiting phosphatidylinositol 3-kinase or Akt but not for death caused by nerve growth factor withdrawal. J. Biol. Chem. 275:2000;34266-34271.
54. Smith D.S., Tsai L.H. Cdk5 behind the wheel: a role in trafficking and transport? Trends Cell Biol. 12:2002;28-36.
55. Sobue K., et al. Interaction of neuronal Cdc2-like protein kinase with microtubule-associated protein tau. J. Biol. Chem. 275:2000;16673-16680.
56. Ko J., et al. p35 and p39 are essential for cyclin-dependent kinase 5 function during neurodevelopment. J. Neurosci. 21:2001;6758-6771.
57. Patrick G.N., et al. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration. Nature. 402:1999;615-622.
58. Bian F., et al. Axonopathy, tau abnormalities, and dyskinesia, but no neurofibrillary tangles in p25-transgenic mice. J. Comp. Neurol. 446:2002;257-266.
59. Trinczek B., et al. Tau regulates the attachment/detachment but not the speed of motors in microtubule-dependent transport of single vesicles and organelles. J. Cell Sci. 112:1999;2355-2367.
60. Stamer K., et al. Tau blocks traffic of organelles, neurofilaments, and APP vesicles in neurons and enhances oxidative stress. J. Cell Biol. 156:2002;1051-1063.
61. Khatoon S., et al. Brain levels of microtubule-associated protein tau are elevated in Alzheimer's disease: a radioimmuno-slot-blot assay for nanograms of the protein. J. Neurochem. 59:1992;750-753.
62. Köpke E., et al. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J. Biol. Chem. 268:1993;24374-24384.
63. Morfini G., et al. Glycogen synthase kinase 3 phosphorylates kinesin light chains and negatively regulates kinesin-based motility. EMBO J. 21:2002;281-293.
64. Lee M.S., et al. Neurotoxicity induces cleavage of p35 to p25 by calpain. Nature. 405:2000;360-364.
65. Oshima M., et al. Nerve growth factor-induced decrease in the calpain activity of PC12 cells. J. Biol. Chem. 264:1989;20811-20816.
66. Nixon R.A. A 'protease activation cascade' in the pathogenesis of Alzheimer's disease. Ann. New York Acad. Sci. 924:2000;117-131.
67. Kamal A., et al. Kinesin-mediated axonal transport of a membrane compartment containing β-secretase and presenilin-1 requires APP. Nature. 414:2001;643-648.
68. Gunawardena S., Goldstein L.S. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron. 32:2001;389-401.
69. Cai, D. et al. Presenilin-1 regulates intracellular trafficking and cell surface delivery of β APP. J. Biol. Chem. (in press).
70. Perry G., et al. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. U. S. A. 84:1987;3033-3036.
71. Morishima-Kawashima M., et al. Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments. Neuron. 10:1993;1151-1160.
72. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron. 29:2001;15-32.
73. Keller J.N., et al. Impaired proteasome function in Alzheimer's disease. J. Neurochem. 75:2000;436-439.
74. Skovronsky D.M., et al. A distinct ER/IC γ -secretase competes with the proteasome for cleavage of APP. Biochemistry. 39:2000;810-817.
75. García-Mata R., et al. Characterization and dynamics of aggresome formation by a cytosolic GFP-chimera. J. Cell Biol. 146:1999;1239-1254.
76. Johnston J.A., et al. Aggresomes: a cellular response to misfolded proteins. J. Cell Biol. 143:1998;1883-1898.
77. Kopito R.R. Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol. 10:2000;524-530.
78. Goedert M., et al. Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations. J. Neurochem. 75:2000;2155-2162.
79. Goedert M. α-synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2:2001;492-501.
80. Polymeropoulos M.H., et al. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science. 276:1997;2045-2047.
81. Lippa C.F., et al. Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol. 153:1998;1365-1370.
82. Lavedan C. The synuclein family. Genome Res. 8:1998;871-880.
83. Shimura H., et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat. Genet. 25:2000;302-305.
84. West A., et al. Complex relationship between Parkin mutations and Parkinson disease. Am. J. Med. Genet. 114:2002;584-591.
85. Leroy E., et al. The ubiquitin pathway in Parkinson's disease. Nature. 395:1998;451-452.
86. Krüger R., et al. Parkinson's disease: one biochemical pathway to fit all genes? Trends Mol. Med. 8:2002;236-240.
87. McNaught K.S., Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci. Lett. 297:2001;191-194.
88. Bonini, N.M. (2002) Chaperoning brain degeneration. Proc. Natl. Acad. Sci. U. S. A. 10.1073/pnas.152330499 (http://www.pnas.org/).
89. Orr H.T. Beyond the Qs in the polyglutamine diseases. Genes Dev. 15:2001;925-932.
90. Niwa J.I., et al. Dorfin ubiquitylates mutant SOD1 and prevents mutant SOD1-mediated neurotoxicity. J. Biol. Chem. 277:2002;36793-36798.
91. Collard J.F., et al. Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis. Nature. 375:1995;61-64.
92. Williamson T.L., Cleveland D.W. Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. Nat. Neurosci. 2:1999;50-56.